Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
3 May 2018
E-000964/2018
Answer given by Mr Andriukaitis on behalf of the Commission

The Commission has analysed the penalties in place in the Member States for the falsification of medicines and misconduct in relation to active substances and excipients. The levels of fines and prison sentences do differ between Member States, but this is a result of national circumstances and legal systems.

In the Commission Report on the Member States’ transposition of Article 118a of Directive 2001/83/EC(1), the Commission calls on Member States to further reinforce their penalties and ensure proper monitoring and enforcement of the penalties in place.

(1)http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52018DC0049&from=EN

Last updated: 15 May 2018Legal notice